Peptide-drug conjugate is a fast-growing area as a new modality for targeted drug delivery with improved efficacy and reduced side effects for cancer treatment. Our comprehensive peptide platform, coupled with our strong small molecule chemistry capability, provides a one-stop solution for peptide drug conjugate development and manufacturing.
Design linkers with optimal size, suitable release mechanism and compatible conjugation chemistry
Develop payload derivatives with modified toxicity and/or special linkage site
Synthesize customized drug-linker complexes
Seamless scale up from discovery to commercial
Sample payload: MMAE, DM1, DM4, PBD, Doxorubicine derivatives etc
Sample linkers: MC-VC-PAB-PNP, Glu-VC-PAB, NHS-Glu-VC-PAB, Azido-Glu-VC-PAB, Hydrazone (acid Sensitive), Disulfide (Glutathione sensitive), SMCC etc
Seamless collaboration with in-parallel activities among 4 workstreams
Swift sample transport and information sharing from upstream to downstream teams